Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Synergy Pharma (SGYP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 591,984
  • Shares Outstanding, K 246,660
  • Annual Sales, $ 0 K
  • Annual Income, $ -198,610 K
  • 36-Month Beta 1,040.57
  • Price/Sales 69.31
  • Price/Cash Flow N/A
  • Price/Book N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.05 +28.78%
on 01/05/18
2.65 -0.38%
on 01/22/18
+0.36 (+15.79%)
since 12/22/17
3-Month
1.68 +57.14%
on 11/15/17
3.19 -17.24%
on 11/06/17
-0.17 (-6.05%)
since 10/20/17
52-Week
1.68 +57.14%
on 11/15/17
7.15 -63.08%
on 01/31/17
-3.27 (-55.33%)
since 01/20/17

Most Recent Stories

More News
Implied Volatility Surging for Synergy Pharmaceuticals (SGYP) Stock Options

Investors need to pay close attention to Synergy Pharmaceuticals (SGYP) stock based on the movements in the options market lately.

SGYP : 2.64 (+10.00%)
Today's Research Reports on Trending Tickers: Supernus Pharmaceuticals and Synergy Pharmaceuticals

NEW YORK, NY / ACCESSWIRE / January 22, 2018 / U.S. markets rebounded on Friday, posting a weekly gain, as positive earnings outweighed worries of a government shutdown. The Dow Jones Industrial Average...

SUPN : 44.25 (-5.65%)
SGYP : 2.64 (+10.00%)
Allergan's (AGN) Sales Guidance for 2018 Lower Than Expected

Allergan (AGN) announces weaker-than-expected sales outlook for 2018. A generic version of Restasis is expected to be launched in Q2.

MYL : 47.64 (+1.95%)
AGN : 188.15 (+3.76%)
SHPG : 147.61 (+1.81%)
SGYP : 2.64 (+10.00%)
Today's Research Reports on Trending Tickers: Amicus Therapeutics, Inc. and Synergy Pharmaceuticals, Inc.

NEW YORK, NY / ACCESSWIRE / January 8, 2018 / U.S. markets continued their impressive run on Friday to close the week with impressive gains. Both the Dow and the Nasdaq have posted its largest four-day...

FOLD : 15.97 (+0.44%)
SGYP : 2.64 (+10.00%)
Allergan to Cut Jobs Amid Loss of Exclusivity for Key Drugs

Allergan (AGN) is laying off over 1,000 employees as part of a cost-cutting and restructuring program as it faces potential loss of exclusivity for some of its key products in 2018.

MYL : 47.64 (+1.95%)
AGN : 188.15 (+3.76%)
SHPG : 147.61 (+1.81%)
SGYP : 2.64 (+10.00%)
The Zacks Analyst Blog Highlights: Synergy Pharmaceuticals, Aradigm and Sucampo Pharmaceuticals

The Zacks Analyst Blog Highlights: Synergy Pharmaceuticals, Aradigm and Sucampo Pharmaceuticals

ARDM : 2.42 (+5.68%)
SCMP : 17.90 (-0.28%)
SGYP : 2.64 (+10.00%)
3 Biotech and Pharma Stocks with FDA Catalysts this January

2017 saw the FDA approving 46 novel drugs as well as path-breaking treatments like Novartis's (NVS) Kymriah and Gilead's Yescarta. Here is a look at three companies expecting a decision this January.

ARDM : 2.42 (+5.68%)
SCMP : 17.90 (-0.28%)
NVS : 87.00 (+0.07%)
GILD : 81.41 (+0.53%)
RHHBY : 30.7900 (+0.33%)
SGYP : 2.64 (+10.00%)
SNY : 43.20 (-3.14%)
Synergy Pharmaceuticals Appoints Troy Hamilton Chief Executive Officer

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced that Troy...

SGYP : 2.64 (+10.00%)
Synergy Pharmaceuticals: Analyst's View, January PDUFA Date and Pipeline Review

NEW YORK, NY / ACCESSWIRE / December 12, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive...

SGYP : 2.64 (+10.00%)
Ironwood Succeeds in Diabetic Hypertension Phase II Study

Ironwood Pharmaceuticals' (IRWD) pipeline candidate, IW-1973, reduces blood pressure and improves metabolic parameters in type II diabetes with hypertension patients in a phase IIa study.

CORT : 24.70 (+3.00%)
IRWD : 15.99 (+3.97%)
AGN : 188.15 (+3.76%)
SGYP : 2.64 (+10.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average.

See More

Business Summary

Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. Its lead drug candidate plecanatide is a guanylyl cyclase C receptor agonist, to treat GI disorders, primarily chronic constipation and constipation-predominant-...

See More

Key Turning Points

2nd Resistance Point 2.86
1st Resistance Point 2.75
Last Price 2.64
1st Support Level 2.43
2nd Support Level 2.22

See More

52-Week High 7.15
Fibonacci 61.8% 5.06
Fibonacci 50% 4.41
Fibonacci 38.2% 3.77
Last Price 2.64
52-Week Low 1.68

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.